NM_000152.5:c.1352C>G
Variant summary
Our verdict is Likely benign. Variant got -5 ACMG points: 0P and 5B. BP4BS1
This summary comes from the ClinGen Evidence Repository: The NM_000152.5:c.1352C>G variant in GAA is a missense variant predicted to result in the substitution of proline by arginine at amino acid 451 (p.Pro451Arg).The highest population minor allele frequency in gnomAD v2.1.1 is 0.00488 (121/24796 alleles, including 2 homozygotes) in the African/African-American population. This allele frequency meets the ClinGen LD VCEP threshold (>0.005) for BS1 (after rounding up). The variant was reported in a patient with limb-girdle muscle weakness but was not thought to be causative of the symptoms (PMID:29149851). The computational predictor REVEL gives a score of 0.449 which is below the threshold of 0.5, evidence that does not predict a damaging effect on GAA function, and SpliceAI predicts no impact on splicing (BP4).There is a ClinVar entry for this variant (Variation ID: 281330). In summary, this variant meets the criteria to be classified as likely benign for Pompe disease. ACMG/AMP criteria applied, as specified by the ClinGen Lysosomal Diseases VCEP (Specifications Version 2.0): BS1, BP4.(Classification approved by the ClinGen Lysosomal Diseases VCEP on May 26, 2023) LINK:https://erepo.genome.network/evrepo/ui/classification/CA8815294/MONDO:0009290/010
Frequency
Consequence
NM_000152.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -5 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.00129 AC: 197AN: 152278Hom.: 2 Cov.: 34
GnomAD3 exomes AF: 0.000380 AC: 95AN: 250328Hom.: 0 AF XY: 0.000214 AC XY: 29AN XY: 135618
GnomAD4 exome AF: 0.000210 AC: 307AN: 1460998Hom.: 2 Cov.: 32 AF XY: 0.000179 AC XY: 130AN XY: 726806
GnomAD4 genome AF: 0.00131 AC: 200AN: 152396Hom.: 2 Cov.: 34 AF XY: 0.00111 AC XY: 83AN XY: 74520
ClinVar
Submissions by phenotype
Glycogen storage disease, type II Benign:5
This variant, c.1352C>G (p.Pro451Arg), has not been reported in the literature in any individuals with Pompe disease, and no results of functional studies are available, to our knowledge. The variant was reported in a patient with limb-girdle muscle weakness but was not thought to be causative of the symptoms (PMID 29149851). The highest population minor allele frequency in gnomAD v.2.1.1 is 0.00488 in the African population, meeting BS1. The score for the REVEL in silico meta-predictor is 0.449, suggesting that the variant does not impact GAA function, meeting BP4. There is a ClinVar entry for this variant (Variation ID: 281330) for which both submitters classify the variant as likely benign. In summary, this variant meets the criteria to be classified as likely benign for Pompe disease. ACMG/AMP criteria applied, as specified by the ClinGen LSD VCEP: BS1, BP4. -
- -
- -
- -
- -
Cardiovascular phenotype Uncertain:1
The p.P451R variant (also known as c.1352C>G), located in coding exon 8 of the GAA gene, results from a C to G substitution at nucleotide position 1352. The proline at codon 451 is replaced by arginine, an amino acid with dissimilar properties. This alteration has been reported in a limb girdle muscular dystrophy cohort and an autism spectrum disorder cohort (Johnson K et al. Orphanet J Rare Dis, 2017 Nov;12:173; Tuncay IO et al. Cell Genom, 2023 Jul;3:100322). This amino acid position is well conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Based on the available evidence, the clinical significance of this variant remains unclear. -
not specified Benign:1
- -
GAA-related disorder Benign:1
This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). -
not provided Benign:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at